Neratinib Recruiting Phase 2 Trials for Cancer, Breast Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01494662HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
NCT03289039Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer